Congress moves to break insurer control over specialty pharmacy networks

What it does

This bill prohibits health insurance plans and insurers from steering patients toward pharmacies they own or control when filling specialty drug prescriptions. It bars plans from charging higher copays for non-affiliated pharmacies, offering financial incentives to use affiliated ones, or creating administrative delays for independent pharmacies. Plans must accept any licensed, qualified specialty pharmacy willing to meet uniform network terms and accept standard reimbursement rates, with narrow exceptions for fraud, Medicare exclusion, or documented patient-safety risk.

Why we flagged it

The bill's core mechanism is a direct prohibition on steering and network exclusion practices that concentrate specialty pharmacy business in insurer-affiliated entities. It is fundamentally a patient-protection and competition measure, not a subsidy, carve-out, or deregulation.

What the text implies

• Effective date of January 1, 2029 delays implementation by ~3 years, giving insurers and PBMs time to restructure affiliated pharmacy arrangements or divest holdings before the rule takes effect.
• Exclusion for 'good cause' (fraud, Medicare suspension, imminent patient harm) is narrow but requires state board or regulatory authority determination, creating potential litigation over what constitutes 'imminent risk'.
• Self-insured group health plans are explicitly exempted from the prohibition, meaning large employers who self-insure retain the ability to steer employees to affiliated pharmacies—limiting the bill's reach to fully-insured plans.
• The bill does not address PBM formulary design, prior authorization, or step therapy—other steering mechanisms that may remain available to plans and PBMs outside the scope of this prohibition.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients gain genuine choice in where to fill specialty prescriptions and protection against cost-shifting designed to funnel them to insurer-owned pharmacies. Independent specialty pharmacies gain market access, increasing competition and potentially lowering prices and improving service quality for patients with complex medication needs.

Who stands to gain

• independent specialty pharmacies
• specialty pharmacy networks not owned by insurers or PBMs
• patients with reduced out-of-pocket costs for specialty drugs

Named in the bill

group health plans, health insurance issuers, specialty pharmacies, affiliated specialty pharmacies, pharmacy benefit managers (PBMs), Joint Commission on Health Care Organizations, Utilization Review Accreditation Commission, Accreditation Commission for Health Care, Medicare, State boards of pharmacy

Where it stands

1 cosponsor: 1 Republicans.

• Sep 24, 2026 — Introduced · Congress.gov: “Introduced in House”
• Sep 24, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.